Benjamin Edwards Inc. Has $381,000 Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Benjamin Edwards Inc. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 232.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,142 shares of the company’s stock after purchasing an additional 798 shares during the period. Benjamin Edwards Inc.’s holdings in Medpace were worth $381,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Stone House Investment Management LLC bought a new position in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new position in shares of Medpace during the 3rd quarter worth approximately $37,000. DT Investment Partners LLC acquired a new position in shares of Medpace during the 2nd quarter worth approximately $41,000. Capital Performance Advisors LLP bought a new stake in Medpace in the 3rd quarter valued at $46,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in Medpace during the second quarter worth $52,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and cut their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Truist Financial reduced their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Finally, TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Trading Up 0.5 %

Shares of MEDP opened at $352.22 on Tuesday. The company has a market capitalization of $10.95 billion, a PE ratio of 30.84, a PEG ratio of 1.94 and a beta of 1.37. The stock’s 50-day moving average price is $338.68 and its two-hundred day moving average price is $368.95. Medpace Holdings, Inc. has a 12 month low of $277.72 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the firm earned $2.22 earnings per share. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. Equities research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.